



Specimen and Request Form Labelling Policy

This procedural document supersedes: PAT/T 8 v.6 - Specimen and Request Form Labelling Policy.



Did you print this document yourself?

The Trust discourages the retention of hard copies of policies and can only guarantee that the policy on the Trust website is the most up-to-date version. **If, for exceptional reasons, you need to print a policy off, it is only valid for 24 hours.**

Executive Sponsor(s):	Moira Hardy
Author/reviewer: (this version)	Richard Stott
Date written/revised:	29 August 2017
Approved by:	Policy Approval and Compliance Group
Date of approval:	13 September 2017
Date issued:	24 October 2017
Next review date:	September 2020
Target audience:	Clinical staff, Trust-wide

Amendment Form

Please record brief details of the changes made alongside the next version number. If the procedural document has been reviewed **without change**, this information will still need to be recorded although the version number will remain the same.

Version	Date Issued	Brief Summary of Changes	Author
Version 7	24 October 2017	<ul style="list-style-type: none"> • New style format included. • Clarification of what constitutes a point of reference. • Revised monitoring section to reflect cessation of SQLAs and Clinical Governance Committee performance target for care groups. • Addition of learning from significant adverse events. 	Dr Richard Stott
Version 6	17 October 2013	<ul style="list-style-type: none"> • New style format included. • Removal of reference to general numbers for neonates. • Addition of criteria for ICE order comms labels. • Link to HSE notice 	Dr Richard Stott
Version 5	February 2011	<ul style="list-style-type: none"> • Use of district number for all Trust requests in place of other patient identification numbers. • Added sample labels consistent with the order communications software due to be introduced from April 2011. 	Dr Richard Stott
Version 4	December 2009	<ul style="list-style-type: none"> • Amendment form and contents page added • Paragraphs numbered • Introduction - addition of - "and patient wrist band (if applicable)." • P7, addition of - "or 'Sharps' included" 	Dr Richard Stott
Version 3	June 2009	Reviewed, no change – Short review time given to coincide with the introduction of new wristbands	Dr Richard Stott
Version 3	February 2007	<ul style="list-style-type: none"> • Alteration to minimum data sets for identification of specimen details (no change to minimum data sets for request form) • Histopathology sample containers should be handwritten • Pre-printed addressograph labels are NOT acceptable on sample containers • Labels printed contemporaneously, will be accepted on sample containers if they include the minimum sample data set and are initialed by the person taking the sample to confirm that they have verified identification with the patient. • Clarification that samples will not be analysed if additional essential information is incomplete 	Dr Wardell

Contents

Paragraph		Page
1	Introduction	4
2	Purpose	4
3	Duties and responsibilities	4
4	Procedure	5
	4.1 Minimum Data Set for Identification on ICE pathology requesting labels.	5
	4.2 Minimum Data Set for Identification on a written request	6
	4.3 Additional Department Specific Details	7
	Blood Transfusion and Blood Grouping Requests	7
	Clinical Biochemistry	7
	Haematology	7
	Microbiology	7
	Histopathology	8
	Cytology	8
	4.4 Additional Information	8
	4.4.1 Unidentified Patient requirements	8
	4.4.2 GUM Patient requirements	8
	4.4.3 Paediatric Samples/Gas syringe requirements	9
	4.4.4 Health and Safety requirements	9
	4.5 Inadequate and Incorrectly Labelled Requests and Unsuitable Samples	9
5	Training / Support	10
6	Monitoring Compliance with the Procedural Document	10
7	Definitions	11
8	Equality Impact Assessment	11
9	Associated Trust Procedural Documents & References	11
Appendix 1	Equality Impact Assessment Part 1 Initial Screening	13

1. INTRODUCTION

Correct sample identification and handling is a mark of good medical practice. Samples that cannot be properly identified because they fail to meet the criteria laid out in this policy are a risk to the patient.

In conjunction with the current version of the Trust's "Patient identification policy" (PAT/PS 7), this policy establishes the minimum identification criteria for Pathology specimens and request forms to be accepted for analysis.

Inadequately or inaccurately labelled specimens or forms will not be accepted unless they are considered to be 'unrepeatable'. A classification of 'unrepeatable' will be on an individual specimen basis following discussion with senior members of Pathology staff and in these cases the requestor may be required to come to the laboratory to amend the request information and document that they have done so. Any labelling discrepancy will be included on the pathology report.

2. PURPOSE

This policy outlines the required information to provide patient identification criteria for Pathology specimens and request forms in order for them to be accepted by the laboratory for analysis.

3. DUTIES AND RESPONSIBILITIES

Pathology will make every effort to ensure requests are processed in a safe and timely manner but it is essential that request forms and samples are labelled appropriately and legibly in compliance with this policy. It is also important to clearly identify the investigations required with relevant supporting information.

- It is the responsibility of managers to ensure that –
 - Staff in their area of responsibility are aware of the content of this policy and the current version of the trust patient identification policy (PAT/PS 7) and follow the required elements for all pathology requests.
 - All patients have been formally identified according to the appropriate sections of the trust patient identification policy. In particular an ID band may be required.
- It is the requestor's responsibility to ensure that –
 - All requestor, location and patient details on the request form or computer screen are correct, clearly legible and that the request form is signed if required for the requested tests (eg blood transfusion related requests).
 - The investigations required are clearly identified with relevant supporting information.

- Any required timings are clearly indicated (eg sample time relative to treatment).
- All appropriate Health & Safety requirements are complied with as detailed in the Health and Safety Policy (CORP/HSFS 1).
- The person responsible for taking the specimen (whether medical, nursing or phlebotomy staff) **MUST** ensure that -
 - All the necessary information is present on the request form. Staff should **NOT** proceed with the specimen collection procedure if this is not the case.
 - Containers are legibly labeled with the correct details of the patient. In particular that the specimen details match those on the form and patient wrist band (if applicable).
 - Containers are securely packaged so they do not leak and are unlikely to be broken on the way to the laboratory.
 - Specimens to be transported by road are packaged in compliance with the Carriage of Dangerous Goods by Road (ADR) Regulations. For details see section 4.5 of the policy on collection & handling of Pathology Specimens (PAT IC 11).
- All Pathology laboratory staff involved in the receipt and testing of specimens are required to ensure that samples and forms are labelled to the standards set out in this document before testing can proceed.

4. PROCEDURE

4.1 Minimum Data Set for Identification on ICE Pathology Requesting Labels.

Each of the following constitutes a single contributor to patient identification, normally all of these will be present on the ICE request form labels :

- **District Number or NHS number (For primary care & other trusts patients)**
- **Patient Surname and Forename (in full, not initials)**
- **Date of birth (DOB)**
- **Gender**
- **Patient address**
- **Request number barcode**

All of this data will correspond to that on CaMIS at the time the label is printed and the patient demographics should always be checked with the patient prior to taking samples.

Printed labels for attaching to sample tubes contain the following data –

- **District Number or NHS number**
- **Patient Surname and Forename**
- **Date of birth (DOB)**
- **Request number barcode**

If the correct procedures are being followed, ICE sample labels will have had their content checked against an ID band or confirmed by the patient at the time they are printed. The patient ID is transmitted electronically to the lab system as well as printed on the labels, therefore this method of requesting is more secure than, and should be used in preference to, hand written forms.

If the patient has moved location since the request was created on ICE it is essential to hand write the correct location on the request form, failure to do so will result in reports being handled as if the original location still applied and may delay action on critical results.

4.2 Minimum Data Set for Identification on a Written Request:

Each of the following constitutes a single contributor to patient identification. A minimum of 3 complete, accurate and legible items must be present on the request form to achieve unique identification of the patient.

- **District Number and/or NHS number (For primary care & other trusts patients)**
- **Patient Surname and Forename (in full, not initials)**
- **Date of birth (DOB)**
- **Patient address if District Number /NHS number not supplied**

A minimum of 3 identical patient identifiers must be present on both the request form and on each individual specimen container to demonstrate that it corresponds with the associated request.

Please note - A district number / NHS number must be provided on any transfusion related request (including antenatal screening).

In addition to the minimum data set for patient identification please ensure all other relevant fields of the request form are completed:

- **Ward/ Practice, Consultant/GP**
- **Patient address**
- **Patient gender**
- **Date and time of collection**
- **Specimen type**
- **Investigation(s) required**
- **Name of requesting clinician and bleep number**
- **Relevant clinical details**
- **Current drug therapy**
- **Copy reports, if required**
- **Patient category (PP/ CAT 2 / NHS)**

Samples may not be analysed if other essential information is incomplete. Please see additional department specific details in section 4.3 for information.

Please Note:

- Pre-printed addressograph labels are NOT acceptable on sample containers (except for samples labeled according to a safe patient identification procedure which has been pre-approved by Pathology).
- Addressograph labels are acceptable on request forms.
- Labels printed contemporaneously (i.e. beside patient and at the time that the sample is being taken) will be accepted on sample tubes if they include the minimum data set **and are initialed by the person taking the sample to confirm that they have verified identification with the patient.** (It is important that the size and thickness of labels placed on samples does not cause difficulties with sample testing. Therefore please seek guidance from the relevant pathology departments before using labels produced by clinical systems).

4.3 Additional Department Specific Details:-

Blood Transfusion and Blood Grouping Requests (see Hospital Blood Transfusion policy PAT/T2). Requests will be rejected (& only emergency O-ve blood packs made available) if the following additional requirements are not followed:-

- **Person taking blood must sign specimen and request form to confirm patient identification has been checked.**
- **A unique patient identifier must be provided (NHS number / District number). This number must be referenced on trust systems ie we cannot accept another trust's locally assigned numbers.**
- Request form must be signed by requesting Doctor.
- Latest Hb result and reason for transfusion, number of units required, time and date required, special requirements e.g. CMV negative or irradiated products required should be indicated on the form.
- Except for emergency transfusions there must be two independent samples tested to provide the patient's blood group and subsequent cross match.

Clinical Biochemistry

- For glucose and lipids, state fasting or non-fasting.
- For drug analysis, time of last dose and time of sample collection are required.
- For antenatal screening for Down's syndrome and NTD, gestational age and patient weight must be provided.
- For pregnancy tests and female hormones, state LMP or day of cycle.
- Patient gender **must** be included for reference ranges to be included on report.

Haematology

- Patient gender must be included for reference ranges to be included on report.

Microbiology

- Include specimen type and site.

- For antibiotic assay levels e.g. Gentamicin, the relevant questions must be answered on the ICE system or a 'Gentamicin sticker' must be applied to the written request form and the following information completed:

Mg of last dose given

Date and Time of last dose

Date and time that sample was taken (pre and post dose samples required for multiple dosing).

Please refer to Gentamicin guidance document. Gentamicin labels are available from Pathology reception.

Histopathology

- Include specimen type and site on both request form and specimen container.
- Indicate patient consent / objection to use of surplus tissue for education / Quality Control.

Cytology

- Include LMP.

4.4 Additional Information

4.4.1 Unidentified Patient Requirements

The request form and samples must contain a unique identifier number (i.e. District number) and patient gender. Where possible, the unique identifier number used should be registered on CaMIS with both forename and surname as 'Unknown'. This enables results to be accessed on ICE by the clinical staff.

Prior registration on systems may not be possible in all cases (e.g. during a MAJAX or failure of computer systems) and, in these cases the request will be entered on to the pathology computer system using a temporary number (T- prefix), the district number as the surname and 'Unknown' as the forename. These results will only be available by searching PAS via patient details. Please refer to Trust Major Incident policy (CORP/RISK 1).

No other data is required and any other data provided must be regarded as provisional until the patient is formally identified.

All request forms must be signed.

4.4.2 Genito-Urinary Medicine (GUM) Patients Requirements

Where name is not appropriate, then GUM number, DOB and gender will be acceptable. The GU med number, gender and date of birth are required and MUST match exactly on the form and sample (odd numbers are male patients).

For use with ICE, existing patients are given a new number which comprises their original numerical identity with a GL prefix. These numbers are registered on the Lilly system and the details are then communicated to ICE & the lab system to permit requesting of tests.

4.4.3 Paediatric Samples/Gas syringe Requirements

Use labels provided and attach to each sample tube

4.4.4 Health and Safety Requirements

In 2011 the HSE issued a reminder regarding the legal requirement to notify certain infection risks on pathology request forms

(<http://www.hse.gov.uk/safetybulletins/clinicalinformation.htm>).

Affix 'Danger of Infection' stickers on samples **and** request forms from patients with the following conditions:

- Hepatitis B, Hepatitis C and HIV
- Cases of infective or suspected infective diseases of the liver
- Known or suspected cases of Mycobacteria (TB)
Salmonella typhi / paratyphi (Typhoid / Paratyphoid)
E.coli 0157
Dysentery with Shigella dysenteriae
Brucellosis
- Patients in at-risk groups

4.5 Inadequate and Incorrectly Labelled Requests and Unsuitable Samples

The Directorate will make every effort to ensure requests are processed in a safe and timely manner but it is essential that request forms and samples are labeled appropriately and legibly in compliance with this policy.

It is also important to clearly identify the investigations required with relevant supporting information.

If you have any doubts regarding this policy please ring the relevant department for further information.

Specimens will **not** be accepted for analysis if: -

- There is no unique identification of the patient i.e. they do not meet the minimum data set for identification.
- Blood transfusion requests without handwritten identification details.
- There is an incorrect sample type or tube.
- Incorrect transportation conditions.
- Sample is received in a hazardous condition e.g. leaking or sharps attached.

- Sample or request form is un-labelled or incorrectly labeled with less than the minimum data sets for patient identification.
- Request form does not include all the essential additional information e.g. fully completed gentamicin label.
- Pre-printed addressograph label used on sample container (with the exception of samples labeled according to safe patient identification procedures and pre-approved by Pathology).
- Mismatch of details between the form and sample(s) .
- The information provided is illegible.

5. TRAINING/ SUPPORT

This policy and the Patient identification policy are no-longer referenced during the Trust induction.

The training requirements of staff will be identified through a training needs analysis. Role specific education will be delivered by the service lead responsible for the specific clinical skill.

- The Trust provides training in phlebotomy techniques and the additional requirements associated with transfusion samples. This training includes all relevant aspects of this policy.
- The trust provides training on aseptic collection of microbiology specimens (Swabs, blood cultures & urines). This training includes all relevant aspects of this policy.
- Training in the use of the ICE order communications system is available via the IT trainers.

6. MONITORING COMPLIANCE WITH PROCEDURAL DOCUMENT

What is being Monitored	Who will carry out the Monitoring	How often	How Reviewed/ Where Reported to
Accuracy of request form & specimen container labelling. Suitability of samples for analysis.	Pathology reception staff.	Every request checked.	As detailed in section 4.5, breaches which prevent analysis will be recorded on outgoing reports in place of the results. Clinical staff may have to re-label unrepeatable specimens before they can be analysed.
Significant breaches are reported as incidents via DATIX.	Reported by Pathology reception staff	In real time via the DATIX process.	To Matrons, ward managers & relevant DATIX investigators.

Performance of individual Care Groups is monitored by pathology.	Logged by Pathology reception staff & analysed by senior staff.	All requests monitored.	Care groups are informed of breaches via the quarterly reports formerly sent as part of the Clinical Governance & Quality meeting's Pathology labelling improvement target. This report is received by Care Group Directors and Clinical Governance leads.
--	---	-------------------------	--

7. DEFINITIONS

ABBREVIATIONS LIST:

- Hb Haemoglobin
- CMV Cytomegalovirus
- NTD Neural Tube Defect
- LMP Last Menstrual Period

8. EQUALITY IMPACT ASSESSMENT

An Equality Impact Assessment (EIA) has been conducted on this procedural document in line with the principles of the Equality Analysis Policy (CORP/EMP 27) and the Fair Treatment For All Policy (CORP/EMP 4).

The purpose of the EIA is to minimise and if possible remove any disproportionate impact on employees on the grounds of race, sex, disability, age, sexual orientation or religious belief. No detriment was identified. (see Appendix 1).

9. ASSOCIATED TRUST PROCEDURAL DOCUMENTS & REFERENCES

- Blood Transfusion Policy - PAT/T 2
- Patient Identification Policy - PAT/PS 7
- Health and Safety Policy - CORP/HSFS 1
- Pathology Specimens – Collection and Handling of Pathology Specimens PAT/IC 11
- Major Incident Plan - CORP/RISK 1
- Fair Treatment for All Policy - CORP/EMP 4
- Equality Analysis Policy - CORP/EMP 27

NB - According to the Patient identification policy, any patients who are unable or unwilling to identify themselves to the required level must be handled by the requesting staff as an “unidentified patient”. Therefore the Trust’s Mental Capacity Act 2005 Policy and

Guidance, including Deprivation of Liberty Safeguards (DoLS)- PAT/PA 19 and the Privacy and Dignity Policy - PAT/PA 28 do not apply to application of this policy.

HSE safety notice HID 5-2011 Provision of key clinical information on laboratory specimen request forms <http://www.hse.gov.uk/safetybulletins/clinicalinformation.htm>

European Agreement Concerning the International Carriage of Dangerous Goods by Road (ADR) Regulations, 2013.

APPENDIX 1 - EQUALITY IMPACT ASSESSMENT PART 1 INITIAL SCREENING

Service/Function/Policy/Project/ Strategy	Care Group/Executive Directorate and Department	Assessor (s)	New or Existing Service or Policy?	Date of Assessment																									
Specimen and Request form labelling policy. PAT/T 8	Diagnostics & Pharmacy care group, Pathology specialties	Dr R. Stott	Revision of existing policy	August 2017																									
1) Who is responsible for this policy: Diagnostics & Pharmacy care group, Pathology specialties																													
2) Describe the purpose of the service / function / policy / project/ strategy? To ensure all pathology requests and specimens are identifiable to a unique patient, site and time.																													
3) Are there any associated objectives? Ensuring the results can be reported to the requesting team, interpreted appropriately and acted on effectively in a timely manner.																													
4) What factors contribute or detract from achieving intended outcomes? – Poor compliance by clinical staff, absence of information at staff induction.																													
5) Does the policy have an impact in terms of age, race, disability, gender, gender reassignment, sexual orientation, marriage/civil partnership, maternity/pregnancy and religion/belief? - None of these are relevant to application of the policy.																													
<ul style="list-style-type: none"> • If yes, please describe current or planned activities to address the impact 																													
6) Is there any scope for new measures which would promote equality? No																													
7) Are any of the following groups adversely affected by the policy?																													
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;">Protected Characteristics</th> <th style="width: 15%;">Affected?</th> <th style="width: 55%;">Impact</th> </tr> </thead> <tbody> <tr> <td>a) Age</td> <td>No</td> <td></td> </tr> <tr> <td>b) Disability</td> <td>No</td> <td></td> </tr> <tr> <td>c) Gender</td> <td>No</td> <td></td> </tr> <tr> <td>d) Gender Reassignment</td> <td>No</td> <td rowspan="9" style="font-size: small;">Please note - Many reference ranges will not apply to individual patients according to the "preferred gender" stated on requests and recorded on CaMIS. Results for these individuals need to be reviewed with care by clinicians who are aware of any hormonal treatments being received and the issues involved with each test.</td> </tr> <tr> <td>e) Marriage/Civil Partnership</td> <td>No</td> </tr> <tr> <td>f) Maternity/Pregnancy</td> <td>No</td> </tr> <tr> <td>g) Race</td> <td>No</td> </tr> <tr> <td>h) Religion/Belief</td> <td>No</td> </tr> <tr> <td>i) Sexual Orientation</td> <td>No</td> </tr> </tbody> </table>					Protected Characteristics	Affected?	Impact	a) Age	No		b) Disability	No		c) Gender	No		d) Gender Reassignment	No	Please note - Many reference ranges will not apply to individual patients according to the "preferred gender" stated on requests and recorded on CaMIS. Results for these individuals need to be reviewed with care by clinicians who are aware of any hormonal treatments being received and the issues involved with each test.	e) Marriage/Civil Partnership	No	f) Maternity/Pregnancy	No	g) Race	No	h) Religion/Belief	No	i) Sexual Orientation	No
Protected Characteristics	Affected?	Impact																											
a) Age	No																												
b) Disability	No																												
c) Gender	No																												
d) Gender Reassignment	No	Please note - Many reference ranges will not apply to individual patients according to the "preferred gender" stated on requests and recorded on CaMIS. Results for these individuals need to be reviewed with care by clinicians who are aware of any hormonal treatments being received and the issues involved with each test.																											
e) Marriage/Civil Partnership	No																												
f) Maternity/Pregnancy	No																												
g) Race	No																												
h) Religion/Belief	No																												
i) Sexual Orientation	No																												
8) Provide the Equality Rating of the service / function / policy / project / strategy – tick (✓) outcome box																													
Outcome 1 ✓	Outcome 2		Outcome 3	Outcome 4																									
*If you have rated the policy as having an outcome of 2, 3 or 4, it is necessary to carry out a detailed assessment and complete a Detailed Equality Analysis form – see CORP/EMP 27.																													
Date for next review: September 2020																													
Checked by: Pathology Clinical Governance Group			Date: August 2017																										